Fig. 1From: MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparibBRCA mutant cell lines demonstrate higher levels of baseline AKT activity. PEO1, PEO4, and SK-OV-3 NTC and BRCA1-kd cells were untreated and levels of phosphorylated and total AKT and S6 proteins were assessed by western blot analysisBack to article page